Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]

Eugene J. Pietzak; Emily C. Zabor; Aditya Bagrodia; Joshua Armenia; Wenhuo Hu; Ahmet Zehir; Samuel Funt; Francois Audenet; David Barron; Noelia Maamouri; Qiang Li; Min Yuen Teo; Maria E. Arcila; Michael F. Berger; Nikolaus Schultz; Guido Dalbagni; Harry W. Herr; Dean F. Bajorin; Jonathan E. Rosenberg; Hikmat Al-Ahmadie; Bernard H. Bochner; David B. Solit; Gopa Iyer

doi:10.1016/j.eururo.2018.09.002

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]

Eugene J. Pietzak, Emily C. Zabor, Aditya Bagrodia, Joshua Armenia, Wenhuo Hu, Ahmet Zehir, Samuel Funt, Francois Audenet, David Barron, Noelia Maamouri, Qiang Li, Min Yuen Teo, Maria E. Arcila, Michael F. Berger, Nikolaus Schultz, Guido Dalbagni, Harry W. Herr, Dean F. Bajorin, Jonathan E. Rosenberg, Hikmat Al-AhmadieBernard H. Bochner, David B. Solit, Gopa Iyer

Research output: Contribution to journal › Article

25 Scopus citations

Abstract

Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.

Original language	English (US)
Pages (from-to)	231-239
Number of pages	9
Journal	European urology
Volume	75
Issue number	2
DOIs	https://doi.org/10.1016/j.eururo.2018.09.002
State	Published - Feb 2019

Keywords

Bladder cancer
ERCC2
Muscle-invasive bladder cancer
Neoadjuvant chemotherapy
Non–muscle-invasive bladder cancer
Radical cystectomy

ASJC Scopus subject areas

Urology

Access to Document

10.1016/j.eururo.2018.09.002

Fingerprint Dive into the research topics of 'Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]'. Together they form a unique fingerprint.

Cite this

Pietzak, E. J., Zabor, E. C., Bagrodia, A., Armenia, J., Hu, W., Zehir, A., Funt, S., Audenet, F., Barron, D., Maamouri, N., Li, Q., Teo, M. Y., Arcila, M. E., Berger, M. F., Schultz, N., Dalbagni, G., Herr, H. W., Bajorin, D. F., Rosenberg, J. E., ... Iyer, G. (2019). Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]. European urology, 75(2), 231-239. https://doi.org/10.1016/j.eururo.2018.09.002

Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]. / Pietzak, Eugene J.; Zabor, Emily C.; Bagrodia, Aditya; Armenia, Joshua; Hu, Wenhuo; Zehir, Ahmet; Funt, Samuel; Audenet, Francois; Barron, David; Maamouri, Noelia; Li, Qiang; Teo, Min Yuen; Arcila, Maria E.; Berger, Michael F.; Schultz, Nikolaus; Dalbagni, Guido; Herr, Harry W.; Bajorin, Dean F.; Rosenberg, Jonathan E.; Al-Ahmadie, Hikmat; Bochner, Bernard H.; Solit, David B.; Iyer, Gopa.

In: European urology, Vol. 75, No. 2, 02.2019, p. 231-239.

Research output: Contribution to journal › Article

Pietzak, EJ, Zabor, EC, Bagrodia, A, Armenia, J, Hu, W, Zehir, A, Funt, S, Audenet, F, Barron, D, Maamouri, N, Li, Q, Teo, MY, Arcila, ME, Berger, MF, Schultz, N, Dalbagni, G, Herr, HW, Bajorin, DF, Rosenberg, JE, Al-Ahmadie, H, Bochner, BH, Solit, DB & Iyer, G 2019, 'Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]', European urology, vol. 75, no. 2, pp. 231-239. https://doi.org/10.1016/j.eururo.2018.09.002

Pietzak, Eugene J. ; Zabor, Emily C. ; Bagrodia, Aditya ; Armenia, Joshua ; Hu, Wenhuo ; Zehir, Ahmet ; Funt, Samuel ; Audenet, Francois ; Barron, David ; Maamouri, Noelia ; Li, Qiang ; Teo, Min Yuen ; Arcila, Maria E. ; Berger, Michael F. ; Schultz, Nikolaus ; Dalbagni, Guido ; Herr, Harry W. ; Bajorin, Dean F. ; Rosenberg, Jonathan E. ; Al-Ahmadie, Hikmat ; Bochner, Bernard H. ; Solit, David B. ; Iyer, Gopa. / Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]. In: European urology. 2019 ; Vol. 75, No. 2. pp. 231-239.

@article{796af1313cda477fb304cce6ae09bc50,

title = "Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]",

abstract = "Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.",

keywords = "Bladder cancer, ERCC2, Muscle-invasive bladder cancer, Neoadjuvant chemotherapy, Non–muscle-invasive bladder cancer, Radical cystectomy",

author = "Pietzak, {Eugene J.} and Zabor, {Emily C.} and Aditya Bagrodia and Joshua Armenia and Wenhuo Hu and Ahmet Zehir and Samuel Funt and Francois Audenet and David Barron and Noelia Maamouri and Qiang Li and Teo, {Min Yuen} and Arcila, {Maria E.} and Berger, {Michael F.} and Nikolaus Schultz and Guido Dalbagni and Herr, {Harry W.} and Bajorin, {Dean F.} and Rosenberg, {Jonathan E.} and Hikmat Al-Ahmadie and Bochner, {Bernard H.} and Solit, {David B.} and Gopa Iyer",

year = "2019",

month = feb,

doi = "10.1016/j.eururo.2018.09.002",

language = "English (US)",

volume = "75",

pages = "231--239",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "2",

}

TY - JOUR

T1 - Genomic Differences Between “Primary” and “Secondary” Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy [Figure presented]

AU - Pietzak, Eugene J.

AU - Zabor, Emily C.

AU - Bagrodia, Aditya

AU - Armenia, Joshua

AU - Hu, Wenhuo

AU - Zehir, Ahmet

AU - Funt, Samuel

AU - Audenet, Francois

AU - Barron, David

AU - Maamouri, Noelia

AU - Li, Qiang

AU - Teo, Min Yuen

AU - Arcila, Maria E.

AU - Berger, Michael F.

AU - Schultz, Nikolaus

AU - Dalbagni, Guido

AU - Herr, Harry W.

AU - Bajorin, Dean F.

AU - Rosenberg, Jonathan E.

AU - Al-Ahmadie, Hikmat

AU - Bochner, Bernard H.

AU - Solit, David B.

AU - Iyer, Gopa

PY - 2019/2

Y1 - 2019/2

N2 - Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.

AB - Patients with secondary muscle-invasive bladder cancer (MIBC) treated with neoadjuvant chemotherapy had worse clinical outcomes than patients treated similarly with primary MIBC. These contrasting clinical outcomes may have resulted from differing rates of cisplatin-sensitizing ERCC2 mutations that were enriched in primary MIBC.

KW - Bladder cancer

KW - ERCC2

KW - Muscle-invasive bladder cancer

KW - Neoadjuvant chemotherapy

KW - Non–muscle-invasive bladder cancer

KW - Radical cystectomy

UR - http://www.scopus.com/inward/record.url?scp=85054135015&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054135015&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2018.09.002

DO - 10.1016/j.eururo.2018.09.002

M3 - Article

C2 - 30290956

AN - SCOPUS:85054135015

VL - 75

SP - 231

EP - 239

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 2

ER -